Eric McClendon
Cardiovascular Disease · Columbus, MSNPI 1841566288
Payments from drug & device makers
What this record shows
25 manufacturers reported payments, led by Medtronic at 25.9% of the total. Reporting peaked in 2023 at $3,186 and has fallen 50.9% since, to $1,563 in 2025.
Across 296 payments — averaging $39.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$2K
- Abiomed$2K
- Edwards Lifesciences$2K
- Abbott$607
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$415
- plus $2K from 19 others
What the payments were for
- Travel & lodging$5,08243%
- Food & beverage$6,71757%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 71 | $3,056 |
| Boston Scientific | 42 | $2,454 |
| Abiomed | 39 | $1,993 |
| Edwards Lifesciences | 13 | $1,551 |
| Abbott | 15 | $607 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $415 |
| Novartis | 23 | $364 |
| AstraZeneca | 11 | $322 |
| Amgen | 11 | $270 |
| Pfizer | 13 | $189 |
| E.r. Squibb & Sons, L.L.C. | 7 | $114 |
| Johnson & Johnson | 4 | $81 |
| Terumo Medical Corporation | 4 | $63 |
| Merck | 3 | $51 |
| Penumbra, Inc. | 2 | $46 |
| Boehringer Ingelheim | 3 | $45 |
| W. L. Gore & Associates, Inc. | 2 | $34 |
| Chiesi USA, Inc. | 2 | $24 |
| Angiodynamics, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $19 |
| Heartflow, Inc. | 1 | $17 |
| Gilead | 1 | $17 |
| Akcea Therapeutics, Inc. | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VersaCross Access Solution$1,657
- CoreValve Evolut$1,383
- Impella$734
- HawkOne$465
- Optis Coronary Imaging System$137
- Repatha$116
- MitraClip$105
How this compares
$11,799 in reported general payments places this provider in the 75th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 219 | $159,277 |
| EntrestoSacubitril/Valsartan | 118 | $91,688 |
| FarxigaDapagliflozin Propanediol | 65 | $63,826 |
| BrilintaTicagrelor | 76 | $53,120 |
| JardianceEmpagliflozin | 36 | $28,899 |
| XareltoRivaroxaban | 35 | $26,047 |
| Metoprolol Succinate | 225 | $2,619 |
| Ranolazine ErRanolazine | 16 | $2,145 |
| Atorvastatin Calcium | 272 | $1,992 |
| ClopidogrelClopidogrel Bisulfate | 192 | $1,186 |
| Carvedilol | 156 | $1,004 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 83 | $722 |
| Isosorbide Dinitrate | 21 | $702 |
| Valsartan | 23 | $687 |
| Furosemide | 182 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $189 | $159,277219 claims |
| AstraZenecaFarxiga, Brilinta | $322 | $116,946141 claims |
| NovartisEntresto | $364 | $91,688118 claims |
| Boehringer IngelheimJardiance | $45 | $28,89936 claims |
| Johnson & JohnsonXarelto | $81 | $26,04735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Columbus
- James WilliamsColumbus$7K
- Dharmesh PatelSouthaven$1.5M
- Barry BertoletTupelo$469K
- Donny StokesJackson$207K
- Mahmoud ZayedPascagoula$103K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Hugo QuintanaPascagoula$48K
- Ediz TasanPascagoula$42K
- Lawrence LeaderHattiesburg$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.